Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.63 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891531 | 1.00 | CHRNB2 (0.63) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS | |
| SCHEMBL12891530 | 1.00 | CHRNB2 (0.63) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS | |
| SCHEMBL10297734 | 0.89 | CHRNB2 (0.53) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS | |
| SCHEMBL29870802 | 0.89 | CHRNB2 (0.53) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS | |
| SCHEMBL8417453 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNA4SIGMAR1CHRNA7HRH3 | |
| SCHEMBL12256567 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNA4SIGMAR1CHRNA7HRH3 | |
| SCHEMBL12891523 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNA4SIGMAR1CHRNA7HRH3 | |
| SCHEMBL23756600 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS | |
| SCHEMBL12993347 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS | |
| SCHEMBL7258173 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4SIGMAR1CHRNA7FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024085661-A1 | NOVEL TRIHETEROCYCLIC COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| US-10233156-B2 | 9-membered fused ring derivative | SHIONOGI & CO., LTD. (JP) | 2019-03-19 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3187492-A1 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY | The University of Tokyo (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2017111076-A1 | α, β UNSATURATED AMIDE COMPOUND | 協和発酵キリン株式会社 | 2017-06-29 | — | — | WO | disclosed |
| US-9079890-B2 | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives | ARRAY BIOPHARMA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | ARRAY BIOPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-7868020-B2 | Quinolynylmethylimidizoles as therapeutic agents | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPPHARMA INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079727-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | CHRNB2 914/4885CHRNA4 2242/4885SIGMAR1 1893/4885 |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | CHRNB2 3742/4885CHRNA4 3318/4885SIGMAR1 4744/4885 |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CHRNB2 2910/4885CHRNA4 2805/4885SIGMAR1 4550/4885 |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | CHRNB2 2740/4885CHRNA4 2207/4885SIGMAR1 903/4885 |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | PDXK, IL4I1, CDK2 | CHRNB2 1562/4885CHRNA4 1626/4885SIGMAR1 4298/4885 |
| US-10233156-B2 | 9-membered fused ring derivative | AGTR2, ACSS2, ACSL3 | CHRNB2 950/4885CHRNA4 2161/4885SIGMAR1 1800/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | CHRNB2 3747/4885CHRNA4 3434/4885SIGMAR1 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.